Circulating 25-hydroxyvitamin D, vitamin D-binding protein and risk of prostate cancer

International Journal of Cancer

Volumn 132, Issue 12, 2013, Pages 2940-2947

  Weinstein, Stephanie J ^a   Mondul, Alison M ^a   Kopp, William ^b   Rager, Helen ^b   Virtamo, Jarmo ^c   Albanes, Demetrius ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

25 hydroxyvitamin D; prospective study; prostate cancer; serum biomarkers; vitamin D binding protein

Indexed keywords

25 HYDROXYVITAMIN D; VITAMIN D BINDING PROTEIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN INTERACTION; RISK ASSESSMENT; RISK FACTOR; VITAMIN BLOOD LEVEL;

ADULT; AGED; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PROSTATIC NEOPLASMS; RISK; VITAMIN D; VITAMIN D-BINDING PROTEIN;

EID: 84876102446     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27969     Document Type: Article

References (50)

1. Holick MF., Vitamin D, deficiency. N Engl J Med 2007; 357: 266-81.
2. IARC. Vitamin D and cancer. Lyon, France: International Agency for Research on Cancer, 2009.
3. Yin L, Raum E, Haug U, et al. Meta-analysis of longitudinal studies: serum vitamin D and prostate cancer risk. Cancer Epidemiol 2009; 33: 435-45.
4. Gilbert R, Martin RM, Beynon R, et al. Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose-response meta-analysis. Cancer Causes Control 2011; 22: 319-40.
5. Gandini S, Boniol M, Haukka J, et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer 2011; 128: 1414-24.
6. Gupta D, Lammersfeld CA, Trukova K, et al. Vitamin D and prostate cancer risk: a review of the epidemiological literature. Prostate Cancer Prostatic Dis 2009; 12: 215-26.
7. Albanes D, Mondul AM, Yu K, et al. Serum 25-hydroxy vitamin D and prostate cancer risk in a large nested case-control study. Cancer Epidemiol Biomarkers Prev 2011; 20: 1850-60.
8. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
9. Speeckaert M, Huang G, Delanghe JR, et al. Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin Chim Acta 2006; 372: 33-42.
10. Cooke NE, Haddad JG., Vitamin D, binding protein. In: Feldman D, Glorieux FH, Pike JW, eds. Vitamin D. San Diego, CA: Academic Press, 1997. 87-101.
11. The ATBC, Cancer Prevention Study Group. The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. Ann Epidemiol 1994; 4: 1-10.
12. Korhonen P, Malila N, Pukkala E, et al. The Finnish Cancer Registry as follow-up source of a large trial cohort-accuracy and delay. Acta Oncol 2002; 41: 381-8.
13. Beahrs O, Henson D, Hutter R, et al. Manual for staging of cancer, 4th edn., American Joint Committee on Cancer. Philadelphia: J.B. Lippincott Company, 1992.
14. Pietinen P, Hartman AM, Haapa E, et al. Reproducibility and validity of dietary assessment instruments. I. A self-administered food use questionnaire with a portion size picture booklet. Am J Epidemiol 1988; 128: 655-66.
15. Fears TR, Ziegler RG, Donaldson JL, et al. Reproducibility studies and interlaboratory concordance for androgen assays in female plasma. Cancer Epidemiol Biomarkers Prev 2000; 9: 403-12.
16. Gallicchio L, Helzlsouer KJ, Chow WH, et al. Circulating 25-hydroxyvitamin D and the risk of rarer cancers: design and methods of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol 2010; 172: 10-20.
17. Willett W, Stampfer MJ,. Total energy intake: implications for epidemiologic analyses. Am J Epidemiol 1986; 124: 17-27.
18. Bikle DD, Gee E, Halloran B, et al. Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein. J Clin Endocrinol Metab 1986; 63: 954-9.
19. Al-oanzi ZH, Tuck SP, Raj N, et al. Assessment of vitamin D status in male osteoporosis. Clin Chem 2006; 52: 248-54.
20. Bouillon R, Van Assche FA, Van Baelen H, et al. Influence of the vitamin D-binding protein on the serum concentration of 1,25-dihydroxyvitamin D3. Significance of the free 1,25-dihydroxyvitamin D3 concentration. J Clin Invest 1981; 67: 589-96.
21. Weinstein SJ, Stolzenberg-Solomon RZ, Kopp W, et al. Impact of circulating vitamin D binding protein levels on the association between 25-hydroxyvitamin D and pancreatic cancer risk: a nested case-control study. Cancer Res 2012; 72: 1190-8.
22. Gilbert R, Metcalfe C, Fraser WD, et al. Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade. Int J Cancer 2012; 131: 1187-96.
23. Brandstedt J, Almquist M, Manjer J, et al. Vitamin D, PTH, and calcium and the risk of prostate cancer: a prospective nested case-control study. Cancer Causes Control 2012; 23: 1377-85.
24. Corder EH, Friedman GD, Vogelman JH, et al. Seasonal variation in vitamin D, vitamin D-binding protein, and dehydroepiandrosterone: risk of prostate cancer in black and white men. Cancer Epidemiol Biomarkers Prev 1995; 4: 655-9.
25. Gann PH, Ma J, Hennekens CH, et al. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev 1996; 5: 121-6.
26. Chishimba L, Thickett DR, Stockley RA, et al. The vitamin D axis in the lung: a key role for vitamin D-binding protein. Thorax 2010; 65: 456-62.
27. Gregory KJ, Zhao B, Bielenberg DR, et al. Vitamin D binding protein-macrophage activating factor directly inhibits proliferation, migration, and uPAR expression of prostate cancer cells. PLoS One 2010; 5: e13428.
28. Pacini S, Punzi T, Morucci G, et al. Effects of vitamin D-binding protein-derived macrophage-activating factor on human breast cancer cells. Anticancer Res 2012; 32: 45-52.
29. Kisker O, Onizuka S, Becker CM, et al. Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice. Neoplasia 2003; 5: 32-40.
30. Arnaud J, Constans J,. Affinity differences for vitamin D metabolites associated with the genetic isoforms of the human serum carrier protein (DBP). Hum Genet 1993; 92: 183-8.
31. Lauridsen AL, Vestergaard P, Hermann AP, et al. Plasma concentrations of 25-hydroxy-vitamin D and 1,25-dihydroxy-vitamin D are related to the phenotype of Gc (vitamin D-binding protein): a cross-sectional study on 595 early postmenopausal women. Calcif Tissue Int 2005; 77: 15-22.
32. Ahn J, Albanes D, Berndt SI, et al. Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk. Carcinogenesis 2009; 30: 769-76.
33. Ahn J, Yu K, Stolzenberg-Solomon R, et al. Genome-wide association study of circulating vitamin D levels. Hum Mol Genet 2010; 19: 2739-45.
34. Wang TJ, Zhang F, Richards JB, et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 2010; 376: 180-8.
35. Chun RF, Adams JS, Hewison M,. Back to the future: a new look at 'old' vitamin D. J Endocrinol 2008; 198: 261-9.
36. Willnow TE, Nykjaer A,. Cellular uptake of steroid carrier proteins-mechanisms and implications. Mol Cell Endocrinol 2010; 316: 93-102.
37. Kaseda R, Hosojima M, Sato H, et al. Role of megalin and cubilin in the metabolism of vitamin D(3). Ther Apher Dial 2011; 15 (Suppl 1): 14-17.
38. Gamat M, Shaw G, Renfree MB,. The role of megalin in prostate development of the mouse (Abstract). Reprod Fertil Dev 2010; 22: 88.
39. Ternes SB, Rowling MJ,. The vitamin D transport protein Dab2 is expressed in prostate and colon epithelial cells and modulated by all-trans-retinoic acid (Abstract). FASEB J 2009; 23: 731. 7.
40. Zheng G, Bachinsky DR, Stamenkovic I, et al. Organ distribution in rats of two members of the low-density lipoprotein receptor gene family, gp330 and LRP/alpha 2MR, and the receptor-associated protein (RAP). J Histochem Cytochem 1994; 42: 531-42.
41. Andreassen TK,. The role of plasma-binding proteins in the cellular uptake of lipophilic vitamins and steroids. Horm Metab Res 2006; 38: 279-90.
42. Rosner W, Hryb DJ, Kahn SM, et al. Interactions of sex hormone-binding globulin with target cells. Mol Cell Endocrinol 2010; 316: 79-85.
43. Wehr E, Pilz S, Boehm BO, et al. Association of vitamin D status with serum androgen levels in men. Clin Endocrinol (Oxf) 2010; 73: 243-8.
44. Holt SK, Karyadi DM, Kwon EM, et al. Association of megalin genetic polymorphisms with prostate cancer risk and prognosis. Clin Cancer Res 2008; 14: 3823-31.
45. Heinonen OP, Albanes D, Virtamo J, et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 1998; 90: 440-6.
46. Haddad JG,. Plasma vitamin D-binding protein (Gc-globulin): multiple tasks. J Steroid Biochem Mol Biol 1995; 53: 579-82.
47. Sonderman JS, Munro HM, Blot WJ, et al. Reproducibility of serum 25-hydroxyvitamin D and vitamin D-binding protein levels over time in a prospective cohort study of black and white adults. Am J Epidemiol 2012; 176: 615-21.
48. Platz EA, Leitzmann MF, Hollis BW, et al. Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 2004; 15: 255-65.
49. Hofmann JN, Yu K, Horst RL, et al. Long-term variation in serum 25-hydroxyvitamin D concentration among participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev 2010; 19: 27-931.
50. Jorde R, Sneve M, Hutchinson M, et al. Tracking of serum 25-hydroxyvitamin D levels during 14 years in a population-based study and during 12 months in an intervention study. Am J Epidemiol 2010; 171: 903-8.